FilingSEC EDGAR8-K
Elicio Therapeutics Reports Q3 Results and Clinical Progress
· SEC accepted
StagePhase 2
Filing content
Elicio Therapeutics reported a reduced net loss for the third quarter and announced clinical data for camupepimut along with its Phase 3 strategy.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…